股市必读：海翔药业（002099）8月18日董秘有最新回复

Core Viewpoint - The stock price of Haixiang Pharmaceutical (002099) has decreased by 1.29% to 6.1 yuan as of August 18, 2025, with a trading volume of 180,100 shares and a turnover of 111 million yuan [1] Group 1: Company Performance and Financial Indicators - The company is expected to report a revenue of approximately 990 to 1,020 million yuan for the first half of 2025, representing a year-on-year decline of about 5% to 7% [1] - The projected net profit attributable to shareholders is estimated to be around 25 to 30 million yuan, indicating a significant year-on-year decrease of approximately 60% to 65% [1] - The gross profit margin is anticipated to be between 26.5% and 27.5%, which is a decline of about 4 to 5 percentage points compared to the same period last year [1] - The return on equity (ROE) is expected to be around 0.45% to 0.55% [1] Group 2: Market Activity and Investor Sentiment - On August 18, 2025, the net outflow of funds from major investors was 12.4 million yuan, while retail investors saw a net inflow of 8.28 million yuan [1] - The trading data indicates that speculative funds had a net inflow of 4.12 million yuan on the same day [1] Group 3: Management and Information Disclosure - The company emphasizes its compliance with relevant laws and regulations regarding information disclosure, stating that all information should be verified through designated media [1] - The company will release its 2025 semi-annual report on August 30, 2025, which will provide official performance data [1]